Renal medullary carcinoma: Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy

Edward M. Schaeffer, Thomas J. Guzzo, Kyle A. Furge, George Netto, Michael Westphal, Karl Dykema, Ximing Yang, Ming Zhou, Bin Tean Teh, Christian P. Pavlovich

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Study Type - Aetiology (case series) Level of Evidence4 OBJECTIVE To present the molecular rationale and potential clinical benefit of topoisomerase II (TopoII)-inhibiting therapy for renal medullary carcinoma (RMC), a rare but extremely lethal form of kidney cancer that classically afflicts young men with sickle-cell trait. The current therapeutic approach with these aggressive tumours is radical nephrectomy followed by systemic chemotherapy, but the prognosis remains dismal. MATERIALS AND METHODS The whole-genome expression was analysed in four RMC tumours. We also report a case of metastatic RMC in which a complete response was achieved for 9 months using a TopoII-inhibiting therapy. RESULTS Expanded whole-genome expression analysis showed increases of TopoII in all cases. There was also overall deregulation of DNA remodelling and repair, and an ontological association between RMC and urothelial carcinoma. Using a TopoII-inhibiting agent, there was a complete response for 9 months in a patient with metastatic RMC. CONCLUSION This report provides molecular evidence for the rational use of TopoII inhibitors in the treatment of RMC.

Original languageEnglish (US)
Pages (from-to)62-65
Number of pages4
JournalBJU International
Volume106
Issue number1
DOIs
StatePublished - Jul 1 2010

Keywords

  • Chemotherapy
  • Renal medullary carcinoma

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Renal medullary carcinoma: Molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy'. Together they form a unique fingerprint.

  • Cite this